Remarkably, in a longitudinal cohort of high-risk individuals, five genes (KIAA1109, T Cell Activation RhoGTPase Activating Protein (TAGAP), Regulator of G Protein Signaling 1 (RGS1), TNFSF14, and SH2B Adaptor Protein 3 (SH2B3)) were overexpressed in PBMCs of CeD patients at least nine months before CeD diagnosis. The gene discussed is BLTP1; the disease is cranioectodermal dysplasia.